$TRVN 'In a call with investors about the Mylan transaction, Pfizer CEO Albert Bourla said his team will continue to look for other deals. He’s eyeing “bolt-on opportunities that would be early-to-midstage opportunities”—deals in which the risk might be higher but chances are better of creating value without disrupting the organization.'
  • 11
  • 3